文献速递妇科肿瘤

一线帕博利珠单抗联合化疗对比安慰剂联合化疗治疗持续性、复发性或转移性宫颈癌:KEYNOTE-826最终总生存结果

First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826.
PubMed 文献 · J Clin Oncol · 2023-11-01

KEYNOTE-826是一项III期双盲试验,评估帕博利珠单抗200 mg或安慰剂每3周一次最多35个周期联合铂类化疗(联合或不联合贝伐珠单抗)治疗持续性、复发性或转移性宫颈癌。最终分析(数据截止2022年10月3日,中位随访39.1个月)显示,在PD-L1 CPS≥1、全人群和CPS≥10人群中,帕博利珠单抗组中位总生存期均优于安慰剂组,风险比分别为0.60、0.63和0.58。

要点

  • PD-L1 CPS≥1人群:帕博利珠单抗组中位OS 28.6个月 vs 安慰剂组16.5个月,HR 0.60。
  • 全人群:帕博利珠单抗组中位OS 26.4个月 vs 安慰剂组16.8个月,HR 0.63。
  • CPS≥10人群:帕博利珠单抗组中位OS 29.6个月 vs 安慰剂组17.4个月,HR 0.58。

核心结论

  • 帕博利珠单抗联合化疗(联合或不联合贝伐珠单抗)在持续性、复发性或转移性宫颈癌患者中持续提供具有临床意义的总生存期改善。

研究设计与样本

  • III期双盲KEYNOTE-826试验,帕博利珠单抗200 mg或安慰剂每3周一次最多35个周期联合铂类化疗(联合或不联合贝伐珠单抗)。
  • 最终数据截止2022年10月3日,中位随访39.1个月(范围32.1-46.5个月)。
  • 分析人群包括PD-L1 CPS≥1(N=548)、全人群(N=617)和CPS≥10(N=317)。

主要发现

  • PD-L1 CPS≥1人群:帕博利珠单抗组中位OS 28.6个月 vs 安慰剂组16.5个月,死亡HR 0.60(95%CI 0.49-0.74)。
  • 全人群:帕博利珠单抗组中位OS 26.4个月 vs 安慰剂组16.8个月,HR 0.63(95%CI 0.52-0.77)。
  • CPS≥10人群:帕博利珠单抗组中位OS 29.6个月 vs 安慰剂组17.4个月,HR 0.58(95%CI 0.44-0.78)。
  • ≥3级不良事件发生率:帕博利珠单抗联合化疗组82.4% vs 安慰剂联合化疗组75.4%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The phase III, double-blind KEYNOTE-826 trial of pembrolizumab 200 mg or placebo once every 3 weeks for up to 35 cycles plus platinum-based chemotherapy, with or without bevacizumab, showed statistically significant survival benefits with the addition of pembrolizumab for patients with persistent, recurrent, or metastatic cervical cancer (primary data cutoff: May 3, 2021). This article reports the protocol-specified final overall survival (OS) results tested in the PD-L1 combined positive score (CPS) ≥1, all-comer, and CPS ≥10 populations. At the final data cutoff (October 3, 2022), the median study follow-up duration was 39.1 months (range, 32.1-46.5 months). In the PD-L1 CPS ≥1 (N = 548), all-comer (N = 617), and CPS ≥10 (N = 317) populations, median OS with pembrolizumab-chemotherapy versus placebo-chemotherapy was 28.6 months versus 16.5 months (hazard ratio [HR] for death, 0.60 [95% CI, 0.49 to 0.74]), 26.4 months versus 16.8 months (HR, 0.63 [95% CI, 0.52 to 0.77]), and 29.6 months versus 17.4 months (HR, 0.58 [95% CI, 0.44 to 0.78]), respectively. The incidence of grade ≥3 adverse events was 82.4% with pembrolizumab-chemotherapy and 75.4% with placebo-chemotherapy. These results show that pembrolizumab plus chemotherapy, with or without bevacizumab, continued to provide clinically meaningful improvements in OS for patients with persistent, recurrent, or metastatic cervical cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Monk BJ, Colombo N, Tewari KS, et al. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. J Clin Oncol. 2023. PMID: 37910822. doi:10.1200/JCO.23.00914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。